These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
149 related articles for article (PubMed ID: 37057217)
1. Comparative-Effectiveness of Oral Beta-Lactams and Fluoroquinolones for Stepdown Therapy in Patients with Enterobacterales Bloodstream Infections: A Retrospective Cohort Study. Bjork L; Hopkins T; Yang L; Teng C; Jones X; Cadena J; Walter E; Frei CR Int J Med Sci; 2023; 20(4):437-443. PubMed ID: 37057217 [No Abstract] [Full Text] [Related]
2. Oral β-lactams vs fluoroquinolones and trimethoprim/sulfamethoxazole for step-down therapy for Escherichia coli, Proteus mirabilis, and Klebsiella pneumoniae bacteremia. McAlister MJ; Rose DT; Hudson FP; Padilla-Tolentino E; Jaso TC Am J Health Syst Pharm; 2023 Feb; 80(Suppl 1):S33-S41. PubMed ID: 35868628 [TBL] [Abstract][Full Text] [Related]
3. Retrospective analysis comparing oral stepdown therapy for enterobacteriaceae bloodstream infections: fluoroquinolones versus β-lactams. Mercuro NJ; Stogsdill P; Wungwattana M Int J Antimicrob Agents; 2018 May; 51(5):687-692. PubMed ID: 29284155 [TBL] [Abstract][Full Text] [Related]
4. Fluoroquinolone versus Beta-Lactam Oral Step-Down Therapy for Uncomplicated Streptococcal Bloodstream Infections. Arensman K; Shields M; Beganovic M; Miller JL; LaChance E; Anderson M; Dela-Pena J Antimicrob Agents Chemother; 2020 Oct; 64(11):. PubMed ID: 32839223 [TBL] [Abstract][Full Text] [Related]
5. Oral β-Lactam Antibiotics vs Fluoroquinolones or Trimethoprim-Sulfamethoxazole for Definitive Treatment of Enterobacterales Bacteremia From a Urine Source. Sutton JD; Stevens VW; Chang NN; Khader K; Timbrook TT; Spivak ES JAMA Netw Open; 2020 Oct; 3(10):e2020166. PubMed ID: 33030555 [TBL] [Abstract][Full Text] [Related]
6. Use of Fluoroquinolones or Sulfamethoxazole-Trimethoprim Compared to Β-Lactams for Oral Step-Down Therapy in Hospitalized Patients With Uncomplicated Enterobacterales Bacteremia. Mack T; Hiles JJ; Wrin J; Desai A Ann Pharmacother; 2023 Mar; 57(3):251-258. PubMed ID: 35758168 [TBL] [Abstract][Full Text] [Related]
7. Oral antibiotics for the treatment of Gram-negative bloodstream infections: A retrospective comparison of three antibiotic classes. Nisly SA; McClain DL; Fillius AG; Davis KA J Glob Antimicrob Resist; 2020 Mar; 20():74-77. PubMed ID: 31390537 [TBL] [Abstract][Full Text] [Related]
8. Oral fluoroquinolones for definitive treatment of gram-negative bacteremia in cancer patients. Tossey JC; El Boghdadly Z; Reed EE; Dela-Pena J; Coe K; Williams SN; Wardlow LC Support Care Cancer; 2021 Sep; 29(9):5057-5064. PubMed ID: 33594513 [TBL] [Abstract][Full Text] [Related]
9. Risk factors for treatment failure in patients receiving β-lactam/β-lactamase inhibitor combinations for Enterobacteriaceae bloodstream infection: A retrospective, single-centre, cohort study. Giannella M; Pascale R; Ferraro G; Toschi A; Pancaldi L; Furii F; Bartoletti M; Tedeschi S; Ambretti S; Lewis RE; Viale P Int J Antimicrob Agents; 2019 May; 53(5):574-581. PubMed ID: 30639527 [TBL] [Abstract][Full Text] [Related]
10. Empirical fluoroquinolones versus broad-spectrum beta-lactams for Gram-negative bloodstream infections in the absence of antimicrobial resistance risk factors. Al-Hasan MN; Gould AP; Drennan C; Hill O; Justo JA; Kohn J; Bookstaver PB J Glob Antimicrob Resist; 2020 Sep; 22():87-93. PubMed ID: 31887412 [TBL] [Abstract][Full Text] [Related]
11. Oral beta-lactam step down in bacteremic E. coli urinary tract infections. Saad S; Mina N; Lee C; Afra K BMC Infect Dis; 2020 Oct; 20(1):785. PubMed ID: 33087051 [TBL] [Abstract][Full Text] [Related]
13. Clinical Benefit of Appropriate Empirical Fluoroquinolone Therapy for Adults with Community-Onset Bacteremia in Comparison with Third-Generation-Cephalosporin Therapy. Lee CC; Wang JL; Lee CH; Hsieh CC; Hung YP; Hong MY; Tang HJ; Ko WC Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27855072 [TBL] [Abstract][Full Text] [Related]
14. Sulfamethoxazole/trimethoprim versus fluoroquinolones for the treatment of Stenotrophomonas maltophilia bloodstream infections. Watson L; Esterly J; Jensen AO; Postelnick M; Aguirre A; McLaughlin M J Glob Antimicrob Resist; 2018 Mar; 12():104-106. PubMed ID: 28964955 [TBL] [Abstract][Full Text] [Related]
15. Cefazolin versus fluoroquinolones for the treatment of community-acquired urinary tract infections in hospitalized patients. Uppala A; King EA; Patel D Eur J Clin Microbiol Infect Dis; 2019 Aug; 38(8):1533-1538. PubMed ID: 31114972 [TBL] [Abstract][Full Text] [Related]
16. Fluoroquinolone therapy for bloodstream infections caused by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae. Lo CL; Lee CC; Li CW; Li MC; Hsueh PR; Lee NY; Ko WC J Microbiol Immunol Infect; 2017 Jun; 50(3):355-361. PubMed ID: 26423244 [TBL] [Abstract][Full Text] [Related]
17. Clinical Risk Score for Prediction of Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae in Bloodstream Isolates. Augustine MR; Testerman TL; Justo JA; Bookstaver PB; Kohn J; Albrecht H; Al-Hasan MN Infect Control Hosp Epidemiol; 2017 Mar; 38(3):266-272. PubMed ID: 27989244 [TBL] [Abstract][Full Text] [Related]